Cullinan Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDCullinan Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 2% provides fundamental context to the price action. However, price is extended 24% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $15.23 | +20.98% | ABOVE |
| 50 SMA | $14.83 | +24.24% | ABOVE |
| 100 SMA | $14.36 | +28.27% | ABOVE |
| 150 SMA | $13.26 | +38.96% | ABOVE |
| 200 SMA | $11.75 | +56.75% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CGEM in an uptrend right now?
CGEM has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CGEM is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CGEM overbought or oversold?
CGEM's RSI (14) is 70. The stock is in neutral territory, neither overbought nor oversold.
Is CGEM outperforming the market?
CGEM has a Relative Strength (RS) Rating of 94 out of 99. Yes, CGEM is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is CGEM in its 52-week range?
CGEM is trading at $18.42, which is 95% of its 52-week high ($19.43) and 93% above its 52-week low ($5.68).
How volatile is CGEM?
CGEM has a Beta of 1.55 and 52-week volatility of 81%. It's more volatile than the S&P 500 - expect bigger swings.